The Hepatitis B Surface Antigen Binding Protein: An Immunoglobulin G Constant Region-Like Protein That Interacts With HBV Envelop Proteins and Mediates HBV Entry

Hepatitis B virus (HBV) infection is a leading cause of liver cirrhosis, liver cancer, and liver failure, affecting 350 million people worldwide. Currently available anti-HBV drugs include (PEGylated-) interferon-α and nucleos(t)ide analogs, which can cause significant side effects and drug-resistance in many cases of long-term treatment. The lack of a reliable and robust in vitro infection system is a major barrier for understanding the HBV life cycle and discovering novel therapeutic targets. In the present study, we demonstrate that overexpression of the hepatitis B surface antigen binding protein (SBP) in HepG2 cells (HepG2-SBP) resulted in their susceptibility to HBV infection. HepG2-SBP cells supported the uptake of the viral surface protein (HBsAg-preS), HBV-pseudotyped virus, and live HBV in patient sera. Moreover, SBP-mediated HBsAg-preS uptake, and HBV pseudotyped virus infections were efficiently blocked by preS1- and SBP-specific antibodies. These observations suggest that SBP is involved in HBV entry and that HepG2-SBP cells can serve as a cellular model to study the post-binding steps of HBV infection.

[1]  J. Kao,et al.  Unmet Needs in Clinical and Basic Hepatitis B Virus Research , 2017, The Journal of infectious diseases.

[2]  K. Ye,et al.  A potent human neutralizing antibody Fc-dependently reduces established HBV infections , 2017, eLife.

[3]  G. Lau,et al.  Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta‐analysis , 2017, Hepatology.

[4]  W. Haefeli,et al.  First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. , 2016, Journal of hepatology.

[5]  K. Chayama,et al.  Early events in hepatitis B virus infection: From the cell surface to the nucleus , 2016, Journal of gastroenterology and hepatology.

[6]  Wenhui Li,et al.  The hepatitis B virus receptor. , 2015, Annual review of cell and developmental biology.

[7]  Z. Rehman,et al.  Deciphering the mystery of hepatitis B virus receptors: A historical perspective , 2015, VirusDisease.

[8]  M. Sugiyama,et al.  Dysregulation of Retinoic Acid Receptor Diminishes Hepatocyte Permissiveness to Hepatitis B Virus Infection through Modulation of Sodium Taurocholate Cotransporting Polypeptide (NTCP) Expression* , 2014, The Journal of Biological Chemistry.

[9]  R. Bartenschlager,et al.  Strategies to inhibit entry of HBV and HDV into hepatocytes. , 2014, Gastroenterology.

[10]  S. Tong,et al.  Identification of NTCP as an HBV receptor: the beginning of the end or the end of the beginning? , 2014, Gastroenterology.

[11]  Wenhui Li,et al.  NTCP and Beyond: Opening the Door to Unveil Hepatitis B Virus Entry , 2014, International journal of molecular sciences.

[12]  Xi Liu,et al.  A human-derived protein SBP (HBsAg-binding protein) can bind to hepatitis B virus surface antigen (HBsAg) and enhance the immune response to hepatitis B virus (HBV) vaccine. , 2013, Molecular immunology.

[13]  Wenhui Li,et al.  Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. , 2012, eLife.

[14]  Y. Ni,et al.  Fine Mapping of Pre-S Sequence Requirements for Hepatitis B Virus Large Envelope Protein-Mediated Receptor Interaction , 2009, Journal of Virology.

[15]  C. Sureau,et al.  The Pre-S1 and Antigenic Loop Infectivity Determinants of the Hepatitis B Virus Envelope Proteins Are Functionally Independent , 2009, Journal of Virology.

[16]  J. Dienstag.  Benefits and risks of nucleoside analog therapy for hepatitis B , 2009, Hepatology.

[17]  M. Hardt,et al.  Hepatitis B virus infection is dependent on cholesterol in the viral envelope , 2009, Cellular microbiology.

[18]  Xu Zhou,et al.  Identification of the critical regions in hepatitis B virus preS required for its stability , 2008, Journal of peptide science : an official publication of the European Peptide Society.

[19]  S. Urban,et al.  Hepatitis B virus infection initiates with a large surface protein–dependent binding to heparan sulfate proteoglycans , 2007 .

[20]  E. Nicolas,et al.  Assembly of Hepatitis B Virus Envelope Proteins onto a Lentivirus Pseudotype That Infects Primary Human Hepatocytes , 2007, Journal of Virology.

[21]  H. Will,et al.  Assembly and budding of a hepatitis B virus is mediated by a novel type of intracellular vesicles , 2007, Hepatology.

[22]  S. Urban,et al.  Viral and cellular determinants involved in hepadnaviral entry. , 2007, World journal of gastroenterology.

[23]  S. Urban,et al.  Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein , 2004 .

[24]  C. Yuanyuan,et al.  Screening, expression and characterization of a novel protein binding to hepatitis B surface antigen , 2005 .

[25]  Chen Yuan.  Screening, Expression and characterization of a Novel Protein Binding to Hepatitis B Surface Antigen , 2005 .

[26]  H. Conjeevaram,et al.  Management of chronic hepatitis B. , 2003, Journal of hepatology.

[27]  Christian Trepo,et al.  Infection of a human hepatoma cell line by hepatitis B virus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  U. Arad.  Modified Hirt procedure for rapid purification of extrachromosomal DNA from mammalian cells. , 1998, BioTechniques.

[29]  Ding‐Shinn Chen,et al.  Hepatitis B Virus Infection , 2007 .

[30]  D. Franco,et al.  Primary cultured normal human hepatocytes for hepatitis B virus receptor studies. , 1996, Journal of hepatology.

[31]  W. Fridman.  Fc receptors and immunoglobulin binding factors 1 , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.